| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft Rejection | 109 | 2025 | 1076 | 15.290 |
Why?
|
| Transplantation Tolerance | 37 | 2024 | 138 | 11.480 |
Why?
|
| B-Lymphocytes | 40 | 2022 | 740 | 8.670 |
Why?
|
| Isoantibodies | 33 | 2025 | 120 | 8.530 |
Why?
|
| Organ Transplantation | 26 | 2024 | 283 | 7.590 |
Why?
|
| Heart Transplantation | 60 | 2024 | 730 | 6.380 |
Why?
|
| Graft Survival | 52 | 2024 | 908 | 5.390 |
Why?
|
| Kidney Transplantation | 25 | 2024 | 856 | 4.510 |
Why?
|
| Immune Tolerance | 25 | 2023 | 341 | 4.160 |
Why?
|
| T-Lymphocytes | 36 | 2024 | 1221 | 3.560 |
Why?
|
| Immunosuppressive Agents | 53 | 2017 | 979 | 3.520 |
Why?
|
| Immunologic Memory | 14 | 2024 | 164 | 3.420 |
Why?
|
| Transplantation, Heterologous | 39 | 2024 | 368 | 3.350 |
Why?
|
| Isoxazoles | 41 | 2006 | 77 | 3.220 |
Why?
|
| CD4-Positive T-Lymphocytes | 15 | 2025 | 450 | 2.780 |
Why?
|
| Mice | 126 | 2024 | 11851 | 2.780 |
Why?
|
| Skin Transplantation | 14 | 2024 | 184 | 2.730 |
Why?
|
| Mice, Inbred BALB C | 41 | 2024 | 1091 | 2.680 |
Why?
|
| Allografts | 17 | 2024 | 184 | 2.610 |
Why?
|
| Animals | 179 | 2025 | 27526 | 2.520 |
Why?
|
| Mice, Inbred C57BL | 52 | 2024 | 3252 | 2.410 |
Why?
|
| Transplantation, Homologous | 41 | 2023 | 995 | 2.400 |
Why?
|
| Lymphocyte Activation | 24 | 2017 | 754 | 2.230 |
Why?
|
| Isoantigens | 12 | 2024 | 71 | 2.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 11 | 2024 | 600 | 2.050 |
Why?
|
| CD40 Ligand | 11 | 2013 | 69 | 1.950 |
Why?
|
| HLA Antigens | 9 | 2023 | 227 | 1.890 |
Why?
|
| Germinal Center | 4 | 2020 | 55 | 1.830 |
Why?
|
| Immunity, Humoral | 4 | 2018 | 66 | 1.740 |
Why?
|
| Islets of Langerhans Transplantation | 16 | 2012 | 242 | 1.710 |
Why?
|
| Transplantation Immunology | 8 | 2019 | 81 | 1.550 |
Why?
|
| Tissue Donors | 13 | 2023 | 504 | 1.520 |
Why?
|
| CTLA-4 Antigen | 8 | 2016 | 140 | 1.520 |
Why?
|
| Immunoglobulin G | 12 | 2023 | 469 | 1.510 |
Why?
|
| Diabetes Mellitus, Experimental | 12 | 2013 | 191 | 1.490 |
Why?
|
| Disaccharides | 11 | 2008 | 23 | 1.370 |
Why?
|
| Antibodies, Monoclonal | 20 | 2023 | 1394 | 1.350 |
Why?
|
| Listeriosis | 6 | 2019 | 86 | 1.340 |
Why?
|
| Toll-Like Receptors | 6 | 2009 | 92 | 1.320 |
Why?
|
| Listeria monocytogenes | 5 | 2019 | 93 | 1.300 |
Why?
|
| Galactosyltransferases | 11 | 2014 | 40 | 1.270 |
Why?
|
| Abatacept | 9 | 2020 | 86 | 1.260 |
Why?
|
| Nanofibers | 7 | 2020 | 32 | 1.250 |
Why?
|
| Major Histocompatibility Complex | 5 | 2023 | 84 | 1.250 |
Why?
|
| Antigen-Presenting Cells | 7 | 2024 | 142 | 1.230 |
Why?
|
| T-Lymphocyte Subsets | 9 | 2019 | 276 | 1.200 |
Why?
|
| Killer Cells, Natural | 13 | 2008 | 276 | 1.180 |
Why?
|
| Rats, Inbred Lew | 38 | 2008 | 197 | 1.170 |
Why?
|
| Humans | 115 | 2025 | 89924 | 1.140 |
Why?
|
| Interferon-gamma | 15 | 2016 | 449 | 1.140 |
Why?
|
| Histocompatibility Antigens Class II | 7 | 2025 | 166 | 1.120 |
Why?
|
| B-Lymphocytes, Regulatory | 3 | 2019 | 8 | 1.110 |
Why?
|
| Bacterial Infections | 4 | 2014 | 184 | 1.080 |
Why?
|
| Disease Models, Animal | 14 | 2024 | 2393 | 1.070 |
Why?
|
| Antibodies | 11 | 2022 | 353 | 1.050 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 2023 | 135 | 1.050 |
Why?
|
| Rats | 54 | 2023 | 4048 | 1.030 |
Why?
|
| Insulin-Secreting Cells | 4 | 2013 | 408 | 1.010 |
Why?
|
| Spleen | 12 | 2020 | 433 | 0.960 |
Why?
|
| Immunoconjugates | 6 | 2016 | 114 | 0.930 |
Why?
|
| B-Lymphocyte Subsets | 3 | 2018 | 40 | 0.920 |
Why?
|
| Primary Graft Dysfunction | 1 | 2024 | 41 | 0.920 |
Why?
|
| Phenanthrenes | 1 | 2023 | 3 | 0.900 |
Why?
|
| Diterpenes | 1 | 2023 | 21 | 0.900 |
Why?
|
| Dendritic Cells | 4 | 2024 | 451 | 0.890 |
Why?
|
| Staphylococcus aureus | 9 | 2022 | 278 | 0.880 |
Why?
|
| Mice, Knockout | 29 | 2019 | 2015 | 0.880 |
Why?
|
| Prodrugs | 1 | 2023 | 51 | 0.870 |
Why?
|
| Staphylococcal Infections | 5 | 2022 | 272 | 0.860 |
Why?
|
| Mice, Transgenic | 16 | 2024 | 1576 | 0.850 |
Why?
|
| Sugars | 1 | 2022 | 3 | 0.840 |
Why?
|
| Regeneration | 5 | 2014 | 151 | 0.830 |
Why?
|
| Antibody Formation | 14 | 2022 | 171 | 0.800 |
Why?
|
| Adaptive Immunity | 6 | 2020 | 167 | 0.790 |
Why?
|
| Diabetes Mellitus, Type 1 | 7 | 2012 | 565 | 0.790 |
Why?
|
| Antigens | 5 | 2022 | 229 | 0.790 |
Why?
|
| Cyclosporine | 20 | 2000 | 238 | 0.770 |
Why?
|
| Female | 49 | 2024 | 46571 | 0.770 |
Why?
|
| Lung Transplantation | 2 | 2024 | 313 | 0.760 |
Why?
|
| Interleukin-10 | 3 | 2017 | 155 | 0.740 |
Why?
|
| Signal Transduction | 13 | 2023 | 3403 | 0.740 |
Why?
|
| Inflammation | 8 | 2022 | 981 | 0.740 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2021 | 11 | 0.740 |
Why?
|
| Killer Cells, Lymphokine-Activated | 10 | 1996 | 27 | 0.700 |
Why?
|
| Pancreas Transplantation | 6 | 2008 | 104 | 0.700 |
Why?
|
| Autoimmunity | 3 | 2019 | 169 | 0.690 |
Why?
|
| Fetus | 2 | 2021 | 232 | 0.690 |
Why?
|
| Kidney | 9 | 2023 | 1148 | 0.680 |
Why?
|
| Congresses as Topic | 1 | 2020 | 115 | 0.670 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2016 | 319 | 0.660 |
Why?
|
| Transplants | 3 | 2022 | 42 | 0.650 |
Why?
|
| Peptides | 9 | 2023 | 649 | 0.650 |
Why?
|
| Desensitization, Immunologic | 1 | 2019 | 37 | 0.650 |
Why?
|
| Complement Activation | 3 | 2008 | 81 | 0.640 |
Why?
|
| Plasma Cells | 3 | 2017 | 85 | 0.640 |
Why?
|
| Mice, Inbred C3H | 12 | 2011 | 371 | 0.630 |
Why?
|
| Th1 Cells | 2 | 2014 | 166 | 0.620 |
Why?
|
| Histocompatibility Antigens Class I | 5 | 2023 | 201 | 0.620 |
Why?
|
| Th2 Cells | 2 | 2014 | 147 | 0.620 |
Why?
|
| Adjuvants, Immunologic | 6 | 2020 | 169 | 0.620 |
Why?
|
| Pregnancy | 5 | 2024 | 3040 | 0.610 |
Why?
|
| Apoptosis | 5 | 2023 | 1718 | 0.600 |
Why?
|
| Immunologic Techniques | 1 | 2017 | 26 | 0.590 |
Why?
|
| Receptors, IgG | 7 | 2008 | 53 | 0.590 |
Why?
|
| Receptors, Antigen, B-Cell | 4 | 2023 | 117 | 0.590 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 684 | 0.580 |
Why?
|
| T-Lymphocytes, Regulatory | 7 | 2022 | 312 | 0.580 |
Why?
|
| Lung | 5 | 2024 | 1292 | 0.580 |
Why?
|
| Cytokines | 9 | 2023 | 811 | 0.570 |
Why?
|
| Staphylococcal Skin Infections | 4 | 2022 | 26 | 0.570 |
Why?
|
| Interleukin-2 | 13 | 2022 | 241 | 0.570 |
Why?
|
| Tumor Necrosis Factor-alpha | 15 | 2017 | 700 | 0.570 |
Why?
|
| Influenza Vaccines | 2 | 2018 | 150 | 0.560 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 2331 | 0.550 |
Why?
|
| Cytotoxicity, Immunologic | 9 | 1995 | 215 | 0.550 |
Why?
|
| Antigens, Differentiation | 7 | 2004 | 141 | 0.530 |
Why?
|
| Transplantation, Heterotopic | 11 | 2010 | 46 | 0.530 |
Why?
|
| B7-H1 Antigen | 4 | 2023 | 278 | 0.530 |
Why?
|
| Clonal Deletion | 3 | 2020 | 23 | 0.520 |
Why?
|
| Male | 48 | 2024 | 42657 | 0.510 |
Why?
|
| Monitoring, Immunologic | 2 | 2015 | 17 | 0.500 |
Why?
|
| Models, Animal | 6 | 2024 | 277 | 0.500 |
Why?
|
| Antigens, CD | 13 | 2018 | 466 | 0.500 |
Why?
|
| Interleukin-6 | 3 | 2011 | 261 | 0.490 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 889 | 0.490 |
Why?
|
| Acute Kidney Injury | 1 | 2019 | 316 | 0.490 |
Why?
|
| Allergy and Immunology | 1 | 2015 | 13 | 0.490 |
Why?
|
| Biomedical Research | 2 | 2020 | 404 | 0.480 |
Why?
|
| Cell Lineage | 1 | 2016 | 293 | 0.480 |
Why?
|
| Precision Medicine | 1 | 2019 | 413 | 0.480 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2018 | 88 | 0.480 |
Why?
|
| Luciferases | 4 | 2013 | 128 | 0.480 |
Why?
|
| Cell Proliferation | 6 | 2019 | 1669 | 0.480 |
Why?
|
| Kidney Failure, Chronic | 2 | 2021 | 414 | 0.480 |
Why?
|
| Laboratories | 1 | 2015 | 44 | 0.480 |
Why?
|
| International Cooperation | 1 | 2015 | 127 | 0.470 |
Why?
|
| CD3 Complex | 8 | 2012 | 134 | 0.460 |
Why?
|
| Islets of Langerhans | 7 | 2010 | 549 | 0.460 |
Why?
|
| Antibodies, Bacterial | 4 | 2022 | 100 | 0.450 |
Why?
|
| Lymph Nodes | 5 | 2024 | 550 | 0.450 |
Why?
|
| Immunization | 4 | 2024 | 163 | 0.450 |
Why?
|
| Antiviral Agents | 5 | 2006 | 482 | 0.440 |
Why?
|
| Membrane Glycoproteins | 9 | 1998 | 431 | 0.440 |
Why?
|
| Uracil | 1 | 2013 | 55 | 0.430 |
Why?
|
| Communicable Diseases | 1 | 2014 | 63 | 0.430 |
Why?
|
| Societies, Medical | 4 | 2022 | 584 | 0.430 |
Why?
|
| Antibodies, Heterophile | 5 | 2004 | 20 | 0.420 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 74 | 0.420 |
Why?
|
| Protein-Tyrosine Kinases | 6 | 1998 | 306 | 0.420 |
Why?
|
| Immunodominant Epitopes | 2 | 2025 | 20 | 0.420 |
Why?
|
| Immunity, Innate | 4 | 2024 | 434 | 0.410 |
Why?
|
| Up-Regulation | 4 | 2010 | 726 | 0.410 |
Why?
|
| Bone Transplantation | 2 | 2003 | 67 | 0.400 |
Why?
|
| Gender Identity | 2 | 2023 | 53 | 0.400 |
Why?
|
| Epitopes | 9 | 2017 | 254 | 0.400 |
Why?
|
| Blood Glucose | 6 | 2016 | 837 | 0.400 |
Why?
|
| Piperidines | 1 | 2013 | 163 | 0.400 |
Why?
|
| Receptors, Immunologic | 6 | 1996 | 136 | 0.390 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 98 | 0.390 |
Why?
|
| Cytomegalovirus | 3 | 2006 | 79 | 0.380 |
Why?
|
| Receptors, Antigen, T-Cell | 7 | 2024 | 395 | 0.380 |
Why?
|
| CD4 Antigens | 6 | 2007 | 83 | 0.380 |
Why?
|
| Hydroxybutyrates | 4 | 1999 | 27 | 0.370 |
Why?
|
| Cytomegalovirus Infections | 4 | 2006 | 150 | 0.370 |
Why?
|
| Vaccines, Subunit | 4 | 2020 | 55 | 0.360 |
Why?
|
| Aniline Compounds | 4 | 1999 | 59 | 0.360 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 351 | 0.360 |
Why?
|
| Tacrolimus | 6 | 2013 | 369 | 0.350 |
Why?
|
| Treatment Outcome | 8 | 2020 | 8270 | 0.350 |
Why?
|
| Lymphocyte Depletion | 3 | 2010 | 98 | 0.340 |
Why?
|
| Bacteria | 1 | 2014 | 486 | 0.340 |
Why?
|
| Liver | 8 | 2008 | 1211 | 0.330 |
Why?
|
| Immunoglobulin M | 8 | 2014 | 164 | 0.320 |
Why?
|
| Phenotype | 9 | 2016 | 2457 | 0.320 |
Why?
|
| Down-Regulation | 1 | 2010 | 520 | 0.320 |
Why?
|
| Insulin | 2 | 2013 | 1148 | 0.320 |
Why?
|
| Uridine | 9 | 2006 | 56 | 0.310 |
Why?
|
| Graft vs Host Disease | 3 | 2009 | 358 | 0.310 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 6 | 1994 | 97 | 0.300 |
Why?
|
| Lymphoproliferative Disorders | 3 | 1997 | 111 | 0.300 |
Why?
|
| Reperfusion Injury | 6 | 2024 | 144 | 0.300 |
Why?
|
| Time Factors | 15 | 2016 | 5357 | 0.300 |
Why?
|
| Biomarkers | 4 | 2023 | 1775 | 0.300 |
Why?
|
| Histocompatibility | 4 | 2023 | 65 | 0.300 |
Why?
|
| alpha-Galactosidase | 1 | 2007 | 5 | 0.300 |
Why?
|
| CD59 Antigens | 1 | 2007 | 17 | 0.300 |
Why?
|
| Cricetinae | 13 | 2000 | 558 | 0.300 |
Why?
|
| Biphenyl Compounds | 2 | 1998 | 59 | 0.290 |
Why?
|
| Ischemic Preconditioning | 2 | 2006 | 37 | 0.290 |
Why?
|
| Antigens, Surface | 1 | 2007 | 102 | 0.290 |
Why?
|
| Risk Factors | 5 | 2024 | 5554 | 0.280 |
Why?
|
| Mesocricetus | 12 | 2000 | 105 | 0.280 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 288 | 0.280 |
Why?
|
| Autoimmune Diseases | 3 | 1998 | 250 | 0.280 |
Why?
|
| Leukocyte Common Antigens | 3 | 1995 | 48 | 0.280 |
Why?
|
| Bone Marrow Transplantation | 3 | 2023 | 283 | 0.270 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 189 | 0.270 |
Why?
|
| Administration, Intranasal | 2 | 2024 | 139 | 0.270 |
Why?
|
| Freund's Adjuvant | 1 | 2006 | 26 | 0.270 |
Why?
|
| Sex Factors | 4 | 2024 | 1075 | 0.270 |
Why?
|
| Cell Transplantation | 1 | 2006 | 47 | 0.260 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 476 | 0.260 |
Why?
|
| NF-kappa B | 4 | 2023 | 469 | 0.260 |
Why?
|
| Consensus | 2 | 2020 | 366 | 0.250 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2014 | 2362 | 0.250 |
Why?
|
| Swine | 10 | 2024 | 590 | 0.250 |
Why?
|
| Endothelium, Vascular | 3 | 2003 | 435 | 0.250 |
Why?
|
| Mice, Inbred Strains | 6 | 2015 | 308 | 0.250 |
Why?
|
| Cell Differentiation | 7 | 2018 | 1533 | 0.250 |
Why?
|
| Cell Adhesion Molecules | 3 | 1994 | 167 | 0.240 |
Why?
|
| Interferon Regulatory Factors | 2 | 2017 | 70 | 0.240 |
Why?
|
| Histocompatibility Testing | 3 | 2023 | 137 | 0.240 |
Why?
|
| Exotoxins | 2 | 2022 | 20 | 0.240 |
Why?
|
| Cells, Cultured | 12 | 2007 | 2887 | 0.240 |
Why?
|
| Acute Disease | 6 | 2009 | 846 | 0.240 |
Why?
|
| Genes, Reporter | 4 | 2019 | 274 | 0.240 |
Why?
|
| Transplantation | 2 | 2024 | 38 | 0.240 |
Why?
|
| Flow Cytometry | 6 | 2018 | 690 | 0.230 |
Why?
|
| Skin | 2 | 2019 | 589 | 0.230 |
Why?
|
| Heterografts | 1 | 2024 | 102 | 0.230 |
Why?
|
| Epoxy Compounds | 1 | 2023 | 9 | 0.220 |
Why?
|
| Antilymphocyte Serum | 2 | 2020 | 70 | 0.220 |
Why?
|
| Cross-Priming | 1 | 2023 | 49 | 0.220 |
Why?
|
| Transplantation Chimera | 3 | 2023 | 81 | 0.210 |
Why?
|
| Cell Line | 12 | 2017 | 2495 | 0.210 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2023 | 27 | 0.210 |
Why?
|
| Organ Specificity | 2 | 2022 | 277 | 0.210 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2022 | 6 | 0.210 |
Why?
|
| Immunoglobulin Class Switching | 2 | 2016 | 38 | 0.210 |
Why?
|
| Antibody Specificity | 2 | 2020 | 130 | 0.210 |
Why?
|
| Myeloid Differentiation Factor 88 | 4 | 2012 | 49 | 0.200 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2020 | 108 | 0.200 |
Why?
|
| Leukocidins | 1 | 2022 | 3 | 0.200 |
Why?
|
| Microbiota | 3 | 2019 | 407 | 0.200 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2024 | 206 | 0.200 |
Why?
|
| Streptozocin | 2 | 2013 | 55 | 0.200 |
Why?
|
| CD8 Antigens | 3 | 2000 | 82 | 0.190 |
Why?
|
| Chronic Disease | 2 | 2024 | 958 | 0.190 |
Why?
|
| Europe | 2 | 2020 | 324 | 0.190 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 4 | 1995 | 11 | 0.190 |
Why?
|
| Publications | 1 | 2021 | 27 | 0.190 |
Why?
|
| Liver Transplantation | 9 | 2002 | 1175 | 0.190 |
Why?
|
| Honey | 1 | 2000 | 3 | 0.190 |
Why?
|
| DNA-Binding Proteins | 5 | 2013 | 1244 | 0.180 |
Why?
|
| Botulism | 1 | 2000 | 6 | 0.180 |
Why?
|
| Interleukin-17 | 2 | 2014 | 105 | 0.180 |
Why?
|
| Tyrosine | 5 | 1999 | 133 | 0.180 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 78 | 0.180 |
Why?
|
| Gene Expression Regulation | 7 | 2021 | 1983 | 0.180 |
Why?
|
| Trans-Activators | 3 | 2013 | 443 | 0.180 |
Why?
|
| H-2 Antigens | 3 | 2020 | 58 | 0.180 |
Why?
|
| Leadership | 1 | 2022 | 141 | 0.180 |
Why?
|
| Nitriles | 6 | 2005 | 156 | 0.180 |
Why?
|
| Antigens, T-Independent | 1 | 2000 | 4 | 0.170 |
Why?
|
| Growth Inhibitors | 3 | 2004 | 41 | 0.170 |
Why?
|
| Green Fluorescent Proteins | 4 | 2014 | 309 | 0.170 |
Why?
|
| Transcription Factors | 4 | 2022 | 1665 | 0.170 |
Why?
|
| Tumor Cells, Cultured | 9 | 1999 | 1048 | 0.170 |
Why?
|
| North America | 1 | 2020 | 188 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 521 | 0.170 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 222 | 0.170 |
Why?
|
| Cell Division | 7 | 1999 | 692 | 0.170 |
Why?
|
| Bacterial Proteins | 2 | 2016 | 901 | 0.170 |
Why?
|
| Macrophages | 4 | 1990 | 582 | 0.160 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 1801 | 0.160 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 2587 | 0.160 |
Why?
|
| Phosphorylation | 7 | 1999 | 1130 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 3 | 2013 | 961 | 0.160 |
Why?
|
| src-Family Kinases | 2 | 1997 | 74 | 0.160 |
Why?
|
| Isoenzymes | 3 | 2013 | 274 | 0.160 |
Why?
|
| fas Receptor | 2 | 1999 | 77 | 0.160 |
Why?
|
| Granzymes | 1 | 2019 | 95 | 0.160 |
Why?
|
| Cytidine Deaminase | 2 | 2016 | 43 | 0.160 |
Why?
|
| Thymus Gland | 1 | 2020 | 197 | 0.160 |
Why?
|
| Glucose Tolerance Test | 3 | 2010 | 227 | 0.160 |
Why?
|
| Crotonates | 4 | 1999 | 12 | 0.160 |
Why?
|
| Toluidines | 4 | 1999 | 18 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 198 | 0.160 |
Why?
|
| Antigen Presentation | 1 | 2020 | 215 | 0.160 |
Why?
|
| Cell Adhesion | 6 | 1995 | 426 | 0.160 |
Why?
|
| Models, Immunological | 2 | 2017 | 81 | 0.150 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2018 | 48 | 0.150 |
Why?
|
| Bacterial Vaccines | 2 | 2017 | 44 | 0.150 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 865 | 0.150 |
Why?
|
| Drug Resistance | 3 | 1993 | 232 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2013 | 665 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 237 | 0.150 |
Why?
|
| Mice, SCID | 2 | 2010 | 259 | 0.150 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 1997 | 10 | 0.150 |
Why?
|
| Mice, Inbred NOD | 6 | 2008 | 198 | 0.150 |
Why?
|
| Neoplasm Proteins | 3 | 1995 | 538 | 0.140 |
Why?
|
| Hybridomas | 3 | 2008 | 75 | 0.140 |
Why?
|
| Oxidoreductases | 1 | 1997 | 112 | 0.140 |
Why?
|
| Clonal Anergy | 1 | 2017 | 31 | 0.140 |
Why?
|
| Mice, Inbred DBA | 3 | 2002 | 150 | 0.140 |
Why?
|
| Autoantibodies | 3 | 2021 | 270 | 0.140 |
Why?
|
| Adoptive Transfer | 6 | 2016 | 169 | 0.140 |
Why?
|
| Leukemia, Experimental | 1 | 1996 | 15 | 0.140 |
Why?
|
| Central Tolerance | 1 | 2016 | 8 | 0.140 |
Why?
|
| Immune Sera | 5 | 2003 | 52 | 0.140 |
Why?
|
| Cell Tracking | 1 | 2016 | 14 | 0.140 |
Why?
|
| Neutralization Tests | 2 | 2014 | 80 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2018 | 142 | 0.130 |
Why?
|
| Integrases | 1 | 2016 | 63 | 0.130 |
Why?
|
| RNA, Untranslated | 1 | 2016 | 65 | 0.130 |
Why?
|
| Cell Movement | 1 | 2020 | 786 | 0.130 |
Why?
|
| Vaccines | 2 | 2014 | 84 | 0.130 |
Why?
|
| Kinetics | 5 | 2016 | 1534 | 0.130 |
Why?
|
| Polysaccharides | 2 | 2014 | 91 | 0.130 |
Why?
|
| Luminescent Proteins | 1 | 2016 | 144 | 0.130 |
Why?
|
| Lymphotoxin-alpha | 2 | 1993 | 44 | 0.130 |
Why?
|
| Biocompatible Materials | 2 | 2014 | 198 | 0.130 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2015 | 11 | 0.130 |
Why?
|
| 5'-Nucleotidase | 1 | 2015 | 13 | 0.130 |
Why?
|
| Peptide Fragments | 3 | 2012 | 463 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 305 | 0.130 |
Why?
|
| Drug Synergism | 3 | 2013 | 307 | 0.130 |
Why?
|
| Hemolysin Proteins | 2 | 2022 | 34 | 0.130 |
Why?
|
| Sirolimus | 2 | 2013 | 162 | 0.120 |
Why?
|
| Diet, High-Fat | 1 | 2016 | 119 | 0.120 |
Why?
|
| Lymphocytes | 3 | 2008 | 468 | 0.120 |
Why?
|
| Plasmodium | 1 | 2014 | 10 | 0.120 |
Why?
|
| Pyrimidine Nucleotides | 3 | 1999 | 7 | 0.120 |
Why?
|
| Organizational Objectives | 1 | 2015 | 24 | 0.120 |
Why?
|
| Malaria, Falciparum | 1 | 2014 | 12 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 3 | 2016 | 798 | 0.120 |
Why?
|
| Gene Regulatory Networks | 1 | 2017 | 310 | 0.120 |
Why?
|
| Bacterial Toxins | 2 | 2022 | 114 | 0.120 |
Why?
|
| Prognosis | 2 | 2014 | 3796 | 0.120 |
Why?
|
| Transfection | 4 | 1998 | 909 | 0.120 |
Why?
|
| Gene Expression | 3 | 2013 | 1309 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2015 | 212 | 0.110 |
Why?
|
| Macromolecular Substances | 1 | 2014 | 177 | 0.110 |
Why?
|
| Rabbits | 2 | 2013 | 640 | 0.110 |
Why?
|
| Antigen-Antibody Complex | 1 | 2014 | 87 | 0.110 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2014 | 20 | 0.110 |
Why?
|
| Cell Cycle Proteins | 1 | 1996 | 399 | 0.110 |
Why?
|
| CD2 Antigens | 4 | 1994 | 22 | 0.110 |
Why?
|
| Research Report | 1 | 2014 | 44 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 179 | 0.110 |
Why?
|
| Nanostructures | 1 | 2014 | 79 | 0.110 |
Why?
|
| Intestine, Small | 4 | 1998 | 299 | 0.110 |
Why?
|
| Antigens, CD20 | 2 | 2012 | 35 | 0.110 |
Why?
|
| Protein Kinase C | 2 | 2013 | 267 | 0.110 |
Why?
|
| Dermatitis | 1 | 2013 | 34 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 1999 | 1929 | 0.110 |
Why?
|
| Luminescent Measurements | 1 | 2013 | 62 | 0.110 |
Why?
|
| Immunity, Cellular | 5 | 2008 | 178 | 0.110 |
Why?
|
| Vaccines, Synthetic | 1 | 2013 | 56 | 0.110 |
Why?
|
| Drug Therapy, Combination | 6 | 1998 | 785 | 0.110 |
Why?
|
| Injections, Intravenous | 2 | 2003 | 238 | 0.100 |
Why?
|
| Immunoglobulins | 1 | 2013 | 143 | 0.100 |
Why?
|
| Complement C4b | 1 | 2012 | 32 | 0.100 |
Why?
|
| Malaria | 1 | 2012 | 23 | 0.100 |
Why?
|
| Syndecan-1 | 1 | 2012 | 18 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 1731 | 0.100 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 311 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1054 | 0.100 |
Why?
|
| Gene Expression Profiling | 3 | 2024 | 1452 | 0.100 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 3 | 1997 | 34 | 0.100 |
Why?
|
| Binding, Competitive | 3 | 1999 | 146 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2022 | 374 | 0.100 |
Why?
|
| Tetradecanoylphorbol Acetate | 3 | 2018 | 137 | 0.100 |
Why?
|
| Escherichia coli | 1 | 2014 | 607 | 0.100 |
Why?
|
| Heat-Shock Proteins | 2 | 2014 | 183 | 0.100 |
Why?
|
| Group Processes | 2 | 2023 | 31 | 0.100 |
Why?
|
| Genotype | 1 | 2016 | 1853 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 100 | 0.100 |
Why?
|
| Viral Proteins | 2 | 2006 | 302 | 0.090 |
Why?
|
| Antigens, Neoplasm | 2 | 2005 | 334 | 0.090 |
Why?
|
| Species Specificity | 4 | 2000 | 685 | 0.090 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 1 | 2014 | 229 | 0.090 |
Why?
|
| Methylprednisolone | 1 | 2011 | 64 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2022 | 4325 | 0.090 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 277 | 0.090 |
Why?
|
| Leukocyte Transfusion | 1 | 2010 | 15 | 0.090 |
Why?
|
| Adult | 8 | 2016 | 26810 | 0.090 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 1990 | 12 | 0.090 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 1995 | 74 | 0.090 |
Why?
|
| Injections, Intraperitoneal | 2 | 2003 | 101 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1992 | 135 | 0.090 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2010 | 33 | 0.090 |
Why?
|
| Th17 Cells | 1 | 2011 | 85 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2006 | 1704 | 0.090 |
Why?
|
| Pancreatic Diseases | 1 | 2010 | 53 | 0.090 |
Why?
|
| Crosses, Genetic | 1 | 2010 | 171 | 0.090 |
Why?
|
| Cell Separation | 3 | 2024 | 199 | 0.090 |
Why?
|
| Cell Death | 3 | 2007 | 261 | 0.090 |
Why?
|
| CD28 Antigens | 2 | 2004 | 90 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 848 | 0.090 |
Why?
|
| CD58 Antigens | 3 | 1994 | 5 | 0.080 |
Why?
|
| Interferon-beta | 1 | 2010 | 126 | 0.080 |
Why?
|
| Obesity | 1 | 2016 | 972 | 0.080 |
Why?
|
| Drug Resistance, Microbial | 2 | 1999 | 75 | 0.080 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2011 | 203 | 0.080 |
Why?
|
| Aging | 1 | 2014 | 727 | 0.080 |
Why?
|
| Monocytes | 1 | 1990 | 221 | 0.080 |
Why?
|
| Gene Knock-In Techniques | 1 | 2009 | 29 | 0.080 |
Why?
|
| Ischemia | 2 | 2014 | 253 | 0.080 |
Why?
|
| Middle Aged | 7 | 2014 | 26132 | 0.080 |
Why?
|
| Lipopolysaccharides | 5 | 2017 | 295 | 0.080 |
Why?
|
| Proteomics | 2 | 2024 | 232 | 0.080 |
Why?
|
| Microspheres | 1 | 1988 | 108 | 0.080 |
Why?
|
| Tandem Repeat Sequences | 1 | 2008 | 29 | 0.080 |
Why?
|
| Heart | 2 | 2016 | 578 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 8 | 1999 | 1237 | 0.080 |
Why?
|
| Biopsy | 1 | 2012 | 1184 | 0.080 |
Why?
|
| Bystander Effect | 1 | 2008 | 12 | 0.080 |
Why?
|
| DNA, Viral | 2 | 1999 | 263 | 0.080 |
Why?
|
| Interleukin-18 | 1 | 2008 | 26 | 0.080 |
Why?
|
| Luminescence | 1 | 2008 | 21 | 0.080 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2008 | 73 | 0.080 |
Why?
|
| Interleukin-1 | 1 | 2008 | 72 | 0.080 |
Why?
|
| Fibroblasts | 3 | 2003 | 759 | 0.080 |
Why?
|
| Ovalbumin | 2 | 2022 | 109 | 0.070 |
Why?
|
| Reference Values | 2 | 2006 | 662 | 0.070 |
Why?
|
| Receptors, Interleukin-2 | 3 | 2005 | 67 | 0.070 |
Why?
|
| Cross Infection | 1 | 2009 | 151 | 0.070 |
Why?
|
| Protein Structure, Secondary | 3 | 2014 | 333 | 0.070 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2008 | 51 | 0.070 |
Why?
|
| Complement System Proteins | 1 | 2008 | 82 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2013 | 816 | 0.070 |
Why?
|
| In Vitro Techniques | 3 | 1995 | 996 | 0.070 |
Why?
|
| Blotting, Northern | 2 | 1999 | 258 | 0.070 |
Why?
|
| Interferon Type I | 1 | 2008 | 186 | 0.070 |
Why?
|
| Ligands | 1 | 2008 | 447 | 0.070 |
Why?
|
| Risk Assessment | 1 | 2014 | 2327 | 0.070 |
Why?
|
| Transcription Factor AP-1 | 2 | 2013 | 65 | 0.070 |
Why?
|
| Protein Binding | 3 | 2020 | 1491 | 0.070 |
Why?
|
| Leukemia, Erythroblastic, Acute | 3 | 1992 | 30 | 0.070 |
Why?
|
| Receptors, Antigen | 1 | 1986 | 11 | 0.070 |
Why?
|
| Rats, Inbred ACI | 4 | 2001 | 25 | 0.070 |
Why?
|
| Rats, Inbred BN | 5 | 2005 | 38 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2001 | 793 | 0.070 |
Why?
|
| Type C Phospholipases | 2 | 1996 | 28 | 0.070 |
Why?
|
| Salivary Glands | 1 | 2006 | 18 | 0.070 |
Why?
|
| Amino Acid Sequence | 4 | 2013 | 2063 | 0.060 |
Why?
|
| Embolism | 1 | 2006 | 33 | 0.060 |
Why?
|
| Lectins, C-Type | 1 | 2006 | 86 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2006 | 162 | 0.060 |
Why?
|
| Age Factors | 3 | 2014 | 1880 | 0.060 |
Why?
|
| Caspases | 1 | 2006 | 155 | 0.060 |
Why?
|
| Carrageenan | 1 | 1985 | 9 | 0.060 |
Why?
|
| Organ Preservation | 2 | 2014 | 119 | 0.060 |
Why?
|
| Bone Marrow | 2 | 1998 | 443 | 0.060 |
Why?
|
| Portal Vein | 1 | 2006 | 121 | 0.060 |
Why?
|
| Enzyme Inhibitors | 3 | 1999 | 644 | 0.060 |
Why?
|
| Autoantigens | 2 | 2016 | 129 | 0.060 |
Why?
|
| Fasting | 2 | 1995 | 162 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2006 | 172 | 0.060 |
Why?
|
| Diabetes Mellitus | 2 | 2004 | 744 | 0.060 |
Why?
|
| Tilapia | 1 | 2004 | 1 | 0.060 |
Why?
|
| Infant | 2 | 2022 | 3189 | 0.060 |
Why?
|
| Interleukin-4 | 2 | 2002 | 129 | 0.060 |
Why?
|
| Molecular Sequence Data | 5 | 2012 | 3024 | 0.060 |
Why?
|
| Immunity | 2 | 2022 | 141 | 0.060 |
Why?
|
| Bias | 1 | 2024 | 135 | 0.060 |
Why?
|
| Young Adult | 4 | 2022 | 6408 | 0.060 |
Why?
|
| Sporozoites | 2 | 2014 | 2 | 0.060 |
Why?
|
| Metabolomics | 1 | 2024 | 76 | 0.060 |
Why?
|
| Antibodies, Protozoan | 2 | 2014 | 42 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2004 | 173 | 0.060 |
Why?
|
| Stem Cells | 1 | 2006 | 376 | 0.050 |
Why?
|
| Binding Sites, Antibody | 1 | 2003 | 49 | 0.050 |
Why?
|
| Chimerism | 1 | 2023 | 37 | 0.050 |
Why?
|
| Myocardium | 2 | 2004 | 573 | 0.050 |
Why?
|
| Cloning, Organism | 1 | 2003 | 19 | 0.050 |
Why?
|
| Antibody Affinity | 1 | 2003 | 38 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 313 | 0.050 |
Why?
|
| Germany | 1 | 2022 | 73 | 0.050 |
Why?
|
| Body Weight | 3 | 2016 | 453 | 0.050 |
Why?
|
| beta-N-Acetylglucosaminylglycopeptide beta-1,4-Galactosyltransferase | 1 | 2002 | 2 | 0.050 |
Why?
|
| Virus Replication | 2 | 2005 | 326 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2006 | 2026 | 0.050 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2001 | 10 | 0.050 |
Why?
|
| Hemin | 1 | 2001 | 5 | 0.050 |
Why?
|
| Erythrocytes | 1 | 2003 | 254 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2001 | 696 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 54 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 1158 | 0.050 |
Why?
|
| Fas Ligand Protein | 2 | 1998 | 49 | 0.050 |
Why?
|
| Gene Ontology | 1 | 2021 | 34 | 0.050 |
Why?
|
| Palatine Tonsil | 1 | 2021 | 30 | 0.050 |
Why?
|
| Genes, Immunoglobulin | 1 | 2001 | 111 | 0.050 |
Why?
|
| Drug Combinations | 2 | 1998 | 203 | 0.050 |
Why?
|
| Scrapie | 1 | 2001 | 2 | 0.050 |
Why?
|
| Clostridium botulinum | 1 | 2000 | 2 | 0.050 |
Why?
|
| Astrocytes | 1 | 2001 | 142 | 0.050 |
Why?
|
| PrPSc Proteins | 1 | 2001 | 22 | 0.050 |
Why?
|
| Janus Kinase 3 | 2 | 1998 | 9 | 0.050 |
Why?
|
| Biolistics | 2 | 1998 | 3 | 0.050 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2000 | 30 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2006 | 3680 | 0.050 |
Why?
|
| Financing, Organized | 1 | 2020 | 12 | 0.050 |
Why?
|
| Neuromuscular Diseases | 1 | 2000 | 31 | 0.050 |
Why?
|
| Adolescent | 4 | 2022 | 9339 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2021 | 50 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 226 | 0.050 |
Why?
|
| Internationality | 1 | 2020 | 70 | 0.040 |
Why?
|
| Administration, Sublingual | 1 | 2020 | 5 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2001 | 200 | 0.040 |
Why?
|
| Trisaccharides | 1 | 2000 | 12 | 0.040 |
Why?
|
| Research Personnel | 1 | 2020 | 72 | 0.040 |
Why?
|
| Bortezomib | 1 | 2020 | 80 | 0.040 |
Why?
|
| Mice, Congenic | 1 | 2019 | 12 | 0.040 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 1999 | 17 | 0.040 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1999 | 12 | 0.040 |
Why?
|
| Foscarnet | 1 | 1999 | 12 | 0.040 |
Why?
|
| Lymphocyte Transfusion | 1 | 2019 | 41 | 0.040 |
Why?
|
| Umbilical Veins | 1 | 1999 | 46 | 0.040 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 1999 | 24 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 1999 | 97 | 0.040 |
Why?
|
| Receptors, Growth Factor | 1 | 1999 | 52 | 0.040 |
Why?
|
| B7-1 Antigen | 2 | 2013 | 76 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 1999 | 90 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1999 | 78 | 0.040 |
Why?
|
| Staphylococcus epidermidis | 1 | 2019 | 15 | 0.040 |
Why?
|
| Neoplasms | 2 | 2024 | 3065 | 0.040 |
Why?
|
| Pancreas | 1 | 2001 | 253 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 156 | 0.040 |
Why?
|
| Neuropeptides | 1 | 1999 | 115 | 0.040 |
Why?
|
| Models, Biological | 2 | 1998 | 1765 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 332 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1999 | 19 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 1999 | 397 | 0.040 |
Why?
|
| Transcriptome | 1 | 2024 | 661 | 0.040 |
Why?
|
| Caspase 1 | 1 | 1998 | 20 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2019 | 171 | 0.040 |
Why?
|
| Leukemia, T-Cell | 1 | 1998 | 17 | 0.040 |
Why?
|
| HT29 Cells | 1 | 1998 | 50 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 1998 | 63 | 0.040 |
Why?
|
| Binding Sites | 2 | 2017 | 1121 | 0.040 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 1998 | 66 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 1998 | 53 | 0.040 |
Why?
|
| Herpesvirus 1, Human | 1 | 2001 | 245 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2003 | 727 | 0.040 |
Why?
|
| Stimulation, Chemical | 2 | 1996 | 63 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1998 | 87 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 1998 | 117 | 0.040 |
Why?
|
| Cell Survival | 2 | 2001 | 983 | 0.040 |
Why?
|
| Cytidine Triphosphate | 1 | 1997 | 2 | 0.040 |
Why?
|
| Uridine Triphosphate | 1 | 1997 | 6 | 0.040 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 1997 | 36 | 0.040 |
Why?
|
| Complement C3 | 1 | 1997 | 58 | 0.040 |
Why?
|
| Fibroblast Growth Factors | 1 | 1998 | 81 | 0.040 |
Why?
|
| Vaccination | 1 | 2020 | 279 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2021 | 337 | 0.040 |
Why?
|
| Immunotherapy, Active | 1 | 2017 | 15 | 0.040 |
Why?
|
| Janus Kinase 1 | 1 | 1997 | 16 | 0.040 |
Why?
|
| Nucleotide Motifs | 1 | 2017 | 49 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 1998 | 266 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 262 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 2767 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2022 | 9203 | 0.040 |
Why?
|
| Particle Size | 1 | 2017 | 126 | 0.040 |
Why?
|
| Cell Membrane | 4 | 2000 | 677 | 0.040 |
Why?
|
| Child | 2 | 2022 | 7242 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 591 | 0.040 |
Why?
|
| Glioma | 1 | 1999 | 294 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 1997 | 231 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 953 | 0.030 |
Why?
|
| Rifabutin | 1 | 1996 | 3 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-vav | 1 | 1996 | 10 | 0.030 |
Why?
|
| Quinones | 1 | 1996 | 9 | 0.030 |
Why?
|
| Lactams, Macrocyclic | 1 | 1996 | 13 | 0.030 |
Why?
|
| Phosphotyrosine | 1 | 1996 | 33 | 0.030 |
Why?
|
| Benzoquinones | 1 | 1996 | 26 | 0.030 |
Why?
|
| Thymocytes | 1 | 2016 | 31 | 0.030 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2016 | 18 | 0.030 |
Why?
|
| Clindamycin | 1 | 2016 | 15 | 0.030 |
Why?
|
| Survival Rate | 1 | 2021 | 1898 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2017 | 107 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 1999 | 498 | 0.030 |
Why?
|
| Antigens, Ly | 1 | 1996 | 37 | 0.030 |
Why?
|
| Leukemia | 2 | 2008 | 322 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2014 | 563 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1607 | 0.030 |
Why?
|
| Verapamil | 2 | 1993 | 34 | 0.030 |
Why?
|
| PrPC Proteins | 1 | 1996 | 13 | 0.030 |
Why?
|
| Diet, Fat-Restricted | 1 | 2016 | 31 | 0.030 |
Why?
|
| Rhodamine 123 | 2 | 1993 | 8 | 0.030 |
Why?
|
| Rhodamines | 2 | 1993 | 18 | 0.030 |
Why?
|
| Neurotoxins | 1 | 1996 | 49 | 0.030 |
Why?
|
| Genistein | 1 | 1995 | 16 | 0.030 |
Why?
|
| Isoflavones | 1 | 1995 | 13 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 1352 | 0.030 |
Why?
|
| Sulfhydryl Reagents | 1 | 1995 | 8 | 0.030 |
Why?
|
| Prions | 1 | 1996 | 54 | 0.030 |
Why?
|
| Kupffer Cells | 1 | 1995 | 13 | 0.030 |
Why?
|
| Vanadates | 1 | 1995 | 32 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1996 | 166 | 0.030 |
Why?
|
| Phospholipase C gamma | 1 | 1995 | 15 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 1995 | 23 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1134 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 209 | 0.030 |
Why?
|
| Anopheles | 1 | 2014 | 4 | 0.030 |
Why?
|
| Recurrence | 3 | 2008 | 1145 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1859 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2015 | 136 | 0.030 |
Why?
|
| Plasmodium falciparum | 1 | 2014 | 47 | 0.030 |
Why?
|
| Macrophage-1 Antigen | 1 | 1994 | 17 | 0.030 |
Why?
|
| Germ-Free Life | 1 | 2014 | 75 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 3769 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 778 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2014 | 19 | 0.030 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2014 | 24 | 0.030 |
Why?
|
| Empyema | 1 | 1994 | 9 | 0.030 |
Why?
|
| Amyloid beta-Peptides | 1 | 1996 | 213 | 0.030 |
Why?
|
| Single-Chain Antibodies | 1 | 2014 | 18 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2014 | 136 | 0.030 |
Why?
|
| Alum Compounds | 1 | 2013 | 5 | 0.030 |
Why?
|
| Nanotechnology | 1 | 2014 | 68 | 0.030 |
Why?
|
| Protein Kinase C-theta | 1 | 2013 | 16 | 0.030 |
Why?
|
| B7-2 Antigen | 1 | 2013 | 40 | 0.030 |
Why?
|
| Ubiquitin | 1 | 2014 | 96 | 0.030 |
Why?
|
| Abdomen | 1 | 1994 | 124 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 2014 | 142 | 0.030 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1993 | 73 | 0.030 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2013 | 15 | 0.030 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2013 | 14 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2013 | 44 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 76 | 0.030 |
Why?
|
| Polyenes | 1 | 1993 | 8 | 0.030 |
Why?
|
| Nitrophenols | 1 | 2013 | 11 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 1994 | 195 | 0.030 |
Why?
|
| Thymidine | 1 | 1993 | 59 | 0.030 |
Why?
|
| Tritium | 1 | 1993 | 133 | 0.030 |
Why?
|
| Propylamines | 1 | 1993 | 9 | 0.030 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2013 | 45 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 693 | 0.030 |
Why?
|
| Rituximab | 1 | 2013 | 117 | 0.030 |
Why?
|
| Organophosphonates | 1 | 2013 | 52 | 0.030 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1992 | 11 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2013 | 91 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 192 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1999 | 1098 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1993 | 244 | 0.030 |
Why?
|
| Autophagy | 1 | 2014 | 159 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 1996 | 1008 | 0.020 |
Why?
|
| Phagocytosis | 2 | 1995 | 86 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 1991 | 66 | 0.020 |
Why?
|
| Receptors, Concanavalin A | 1 | 1991 | 1 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2019 | 2313 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2012 | 188 | 0.020 |
Why?
|
| Gamma Rays | 1 | 1991 | 73 | 0.020 |
Why?
|
| Alpha-Globulins | 1 | 1990 | 11 | 0.020 |
Why?
|
| alpha 1-Antitrypsin | 1 | 1990 | 16 | 0.020 |
Why?
|
| Lymphoma | 2 | 1990 | 266 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1990 | 50 | 0.020 |
Why?
|
| Calcium | 1 | 1995 | 1179 | 0.020 |
Why?
|
| Colony-Forming Units Assay | 1 | 1990 | 40 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1990 | 37 | 0.020 |
Why?
|
| Aged | 3 | 2014 | 19240 | 0.020 |
Why?
|
| Skin Diseases | 1 | 1992 | 174 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 1995 | 417 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 1991 | 173 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 740 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1990 | 32 | 0.020 |
Why?
|
| Tissue and Organ Procurement | 1 | 2014 | 359 | 0.020 |
Why?
|
| Killer Factors, Yeast | 1 | 1989 | 1 | 0.020 |
Why?
|
| Cell-Free System | 1 | 1989 | 51 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 1989 | 21 | 0.020 |
Why?
|
| Periodic Acid | 1 | 1988 | 4 | 0.020 |
Why?
|
| Oligosaccharides | 1 | 1988 | 24 | 0.020 |
Why?
|
| Neuraminidase | 1 | 1988 | 46 | 0.020 |
Why?
|
| Trypsin | 1 | 1988 | 95 | 0.020 |
Why?
|
| Biological Assay | 1 | 1989 | 79 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 2009 | 92 | 0.020 |
Why?
|
| Clone Cells | 1 | 1989 | 214 | 0.020 |
Why?
|
| Pluripotent Stem Cells | 1 | 2008 | 34 | 0.020 |
Why?
|
| ROC Curve | 1 | 2010 | 778 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 1998 | 154 | 0.020 |
Why?
|
| Rodentia | 1 | 2007 | 41 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 885 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 264 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 1995 | 1227 | 0.020 |
Why?
|
| Base Sequence | 2 | 2001 | 2329 | 0.020 |
Why?
|
| Rosette Formation | 1 | 1986 | 34 | 0.020 |
Why?
|
| Thioglycolates | 1 | 1986 | 2 | 0.020 |
Why?
|
| Mycobacterium bovis | 1 | 1986 | 16 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2008 | 305 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 1469 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 2 | 1997 | 40 | 0.020 |
Why?
|
| Rose Bengal | 1 | 1985 | 3 | 0.020 |
Why?
|
| Polyelectrolytes | 1 | 1985 | 6 | 0.020 |
Why?
|
| Colorimetry | 1 | 1985 | 8 | 0.020 |
Why?
|
| Endocytosis | 1 | 1986 | 180 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 1985 | 172 | 0.020 |
Why?
|
| Carbohydrates | 1 | 1985 | 47 | 0.020 |
Why?
|
| Alkynes | 1 | 2005 | 18 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2004 | 36 | 0.020 |
Why?
|
| Alleles | 1 | 2008 | 1139 | 0.010 |
Why?
|
| Neutrophils | 1 | 1986 | 311 | 0.010 |
Why?
|
| Genetic Variation | 1 | 1991 | 1380 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 559 | 0.010 |
Why?
|
| Membranes | 1 | 2004 | 37 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2008 | 689 | 0.010 |
Why?
|
| Polymers | 1 | 1985 | 196 | 0.010 |
Why?
|
| Temperature | 1 | 1985 | 409 | 0.010 |
Why?
|
| Proteins | 1 | 1989 | 786 | 0.010 |
Why?
|
| Nuclear Transfer Techniques | 1 | 2003 | 15 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2005 | 326 | 0.010 |
Why?
|
| Immunoglobulin D | 1 | 2002 | 5 | 0.010 |
Why?
|
| Leukosialin | 1 | 2002 | 16 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 31 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 223 | 0.010 |
Why?
|
| Phenanthrolines | 1 | 2001 | 7 | 0.010 |
Why?
|
| Pregnatrienes | 1 | 2001 | 14 | 0.010 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 2001 | 25 | 0.010 |
Why?
|
| Butadienes | 1 | 2001 | 34 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2001 | 109 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2001 | 53 | 0.010 |
Why?
|
| Free Radicals | 1 | 2001 | 71 | 0.010 |
Why?
|
| Calcineurin Inhibitors | 1 | 2002 | 53 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2001 | 72 | 0.010 |
Why?
|
| Flavonoids | 1 | 2001 | 84 | 0.010 |
Why?
|
| Prednisone | 1 | 2002 | 255 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2001 | 149 | 0.010 |
Why?
|
| Endopeptidase K | 1 | 2001 | 12 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 262 | 0.010 |
Why?
|
| Creatinine | 1 | 2002 | 294 | 0.010 |
Why?
|
| Vero Cells | 1 | 2001 | 103 | 0.010 |
Why?
|
| Anemia | 1 | 2002 | 132 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 293 | 0.010 |
Why?
|
| Antioxidants | 1 | 2001 | 226 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2004 | 603 | 0.010 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2000 | 13 | 0.010 |
Why?
|
| GA-Binding Protein Transcription Factor | 1 | 1999 | 2 | 0.010 |
Why?
|
| Splanchnic Circulation | 1 | 1999 | 14 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 1999 | 77 | 0.010 |
Why?
|
| Liver Circulation | 1 | 1999 | 29 | 0.010 |
Why?
|
| Neurons | 2 | 2001 | 1591 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 1999 | 88 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 6780 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 2000 | 0.010 |
Why?
|
| Thalamus | 1 | 2001 | 134 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 126 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1999 | 207 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2001 | 490 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2001 | 458 | 0.010 |
Why?
|
| STAT6 Transcription Factor | 1 | 1998 | 28 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1998 | 160 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1997 | 19 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2001 | 591 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1997 | 72 | 0.010 |
Why?
|
| Hematoxylin | 1 | 1997 | 6 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1999 | 284 | 0.010 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 1997 | 11 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1999 | 602 | 0.010 |
Why?
|
| Hippocampus | 1 | 2001 | 449 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 1998 | 280 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 2018 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1996 | 71 | 0.010 |
Why?
|
| Circular Dichroism | 1 | 1996 | 117 | 0.010 |
Why?
|
| PC12 Cells | 1 | 1996 | 115 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1995 | 11 | 0.010 |
Why?
|
| Marine Toxins | 1 | 1995 | 7 | 0.010 |
Why?
|
| Okadaic Acid | 1 | 1995 | 10 | 0.010 |
Why?
|
| Dithiothreitol | 1 | 1995 | 25 | 0.010 |
Why?
|
| Ethers, Cyclic | 1 | 1995 | 8 | 0.010 |
Why?
|
| Oxazoles | 1 | 1995 | 18 | 0.010 |
Why?
|
| Cations, Divalent | 1 | 1995 | 39 | 0.010 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1995 | 58 | 0.010 |
Why?
|
| Naphthalenes | 1 | 1995 | 42 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 1997 | 373 | 0.010 |
Why?
|
| Bile | 1 | 1995 | 58 | 0.010 |
Why?
|
| Glycogen | 1 | 1995 | 59 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1996 | 515 | 0.010 |
Why?
|
| Duodenal Neoplasms | 1 | 1994 | 19 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 1995 | 388 | 0.010 |
Why?
|
| Ileostomy | 1 | 1994 | 29 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 1995 | 355 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 1995 | 195 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1996 | 508 | 0.010 |
Why?
|
| Leiomyosarcoma | 1 | 1994 | 45 | 0.010 |
Why?
|
| Weight Gain | 1 | 1994 | 119 | 0.010 |
Why?
|
| Chloroquine | 1 | 1993 | 12 | 0.010 |
Why?
|
| Protein Processing, Post-Translational | 1 | 1995 | 383 | 0.010 |
Why?
|
| Stearic Acids | 1 | 1993 | 11 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 1993 | 54 | 0.010 |
Why?
|
| Perforin | 1 | 1993 | 55 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1994 | 591 | 0.010 |
Why?
|
| Protein Conformation | 1 | 1995 | 895 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1992 | 18 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1994 | 569 | 0.010 |
Why?
|
| Actins | 1 | 1995 | 462 | 0.010 |
Why?
|
| Probability | 1 | 1993 | 350 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1996 | 400 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1991 | 20 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1992 | 224 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1993 | 899 | 0.010 |
Why?
|
| Biological Transport | 1 | 1991 | 401 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 919 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1993 | 360 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1990 | 43 | 0.010 |
Why?
|
| RNA | 1 | 1993 | 583 | 0.000 |
Why?
|
| Interferons | 1 | 1989 | 127 | 0.000 |
Why?
|
| DNA | 1 | 1993 | 1311 | 0.000 |
Why?
|